Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Brodalumab binds to IL17RA

Class:IdReaction:9716007
_displayNameBrodalumab binds to IL17RA
_doReleaseFALSE
_timestamp2021-02-19 10:57:48
authored[InstanceEdit:9715980] Stephan, Ralf, 2021-02-18
compartment[Compartment:984] extracellular region
created[InstanceEdit:9715972] Stephan, Ralf, 2021-02-19
input[ProteinDrug:9715965] brodalumab [extracellular region]
[EntityWithAccessionedSequence:447176] IL17RA [plasma membrane] [Homo sapiens]
isChimericFALSE
literatureReference[LiteratureReference:9716025] Malignancy Rates in Brodalumab Clinical Studies for Psoriasis
[LiteratureReference:9716023] Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy
[LiteratureReference:9716006] Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis
[LiteratureReference:9716027] Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
nameBrodalumab binds to IL17RA
output[Complex:9716009] brodalumab:IL17RA [plasma membrane] [Homo sapiens]
species[Species:48887] Homo sapiens
stableIdentifier[StableIdentifier:9716030] R-HSA-9716007.1
summation[Summation:9715961] Brodalimumab is an interleukin-17 receptor A/C complex antag...
(hasEvent)[Pathway:448424] Interleukin-17 signaling [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by Brodalumab binds to IL17RA (9716007)
Follow Reactome